Navigation Links
Raging Capital Sends Letter to Taro Pharmaceutical Board of Directors in Opposition to Inadequate Acquisition Offer by Sun Pharmaceutical
Date:11/3/2011

o which Sun Pharma acquired one-third of the voting power of Taro's capital stock.  By the end of September 2010, Sun Pharma had acquired control of the Taro Board and majority control of the Company's voting power.  We fear that Sun Pharma is now trying to use its leverage to squeeze out the minority shareholders at a price that deprives them of the full value of their investment.

To ensure fair price in a transaction that maximizes value for minority shareholders, the Board must engage independent financial and legal advisors to help the Company either negotiate a fair price with Sun Pharma for the sale of Taro's minority publicly traded shares or conduct a robust and unbiased auction allowing the Company to identify a buyer willing to pay a fair price for Taro's public shares.  Minority shareholders have rights accorded to them that must be protected and Sun Pharma should not be allowed to unilaterally impose the Acquisition Proposal on the minority shareholders of Taro without the advice of independent advisors and the approval of a disinterested body of directors.

For all these reasons, we believe the Acquisition Proposal woefully shortchanges Taro shareholders.  Unless and until the Board commits itself to a course of action that is consistent with its fiduciary duties, we remain vehemently opposed to the Acquisition Proposal and will vigorously campaign against it.  We are currently evaluating all legal options and reserve our rights to take any action necessary to ensure that the Company is run in a manner that is consistent with the best interests of the non-Sun Pharma shareholders.  Rest assured we will do all that we can to ensure that shareholders receive the maximum value for their investment in the Company.

Sincerely,

William C. Martin
Chairman and Chief Investment Officer

Investor Contact:
William C. Martin
Raging Capital Management, LLC
(917) 549-8868

<
'/>"/>
SOURCE Raging Capital Management, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Delcath Announces Encouraging Top-Line Results From Hepatobiliary Cohort in Phase II Trial of Chemosaturation System
2. SAR 1118 Demonstrates Encouraging Results in Phase 2 Study of Dry Eye Disease
3. comScore Announces Availability of Media Planning Tool Leveraging Behavioral Insights into Online Usage Habits of Doctors
4. Power Wheelchair From Medicare Helps Save Elderly Alabama Woman From Raging Fire That Destroyed Her Home of 40 Years
5. Stimatix GI Reports Encouraging Interim Results
6. Mississippians React to Rushed Pseudoephedrine Debate Raging in the State Legislature
7. Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution
8. Patients who Participated in Pleio GoodStart(TM) Refilled 30% Sooner and 40% More, Averaging 2 Additional Rx Refills per Patient
9. AFFiRiS AG - Encouraging Results From Phase I Studies of two Alzheimers Candidate Vaccines Trigger a EUR 10 Million Milestone Payment
10. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
11. Encouraging First Data on New Targeted Treatment for Patients With Melanoma - the Deadliest Form of Skin Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... --  Decision Resources Group finds that the sports ... will continue to be hindered in the near term ... longer timeline, however, the outlook is improved. Expanding populations ... the prevalence of osteoarthritic damage and sports-related injuries that ... solutions. Coupled with continuing economic recovery across ...
(Date:7/29/2015)... , July 29, 2015  PDL BioPharma, Inc. ... entered into a revenue interest assignment agreement (the "Agreement") ... Inc. (NASDAQ: ARIA ) with up to $200 ... on the net revenues of Iclusig ® (ponatinib).  ... in two tranches of $50 million each, with the ...
(Date:7/29/2015)... MELVILLE, N.Y., July 29, 2015  Henry Schein, ... provider of health care products and services to ... reported record second quarter financial results. ... 2015 were $2.6 billion, an increase of 0.5% ... consisted of 7.5% growth in local currencies and ...
Breaking Medicine Technology:The Long-Term Outlook for European Sports Medicine Device Markets Remains Positive, with Economic Recovery and Expanding Patient Populations Supporting Growth Through 2023 2The Long-Term Outlook for European Sports Medicine Device Markets Remains Positive, with Economic Recovery and Expanding Patient Populations Supporting Growth Through 2023 3PDL BioPharma Completes Royalty Transaction with ARIAD Pharmaceuticals 2PDL BioPharma Completes Royalty Transaction with ARIAD Pharmaceuticals 3PDL BioPharma Completes Royalty Transaction with ARIAD Pharmaceuticals 4PDL BioPharma Completes Royalty Transaction with ARIAD Pharmaceuticals 5Henry Schein Reports Record Second Quarter Results 2Henry Schein Reports Record Second Quarter Results 3Henry Schein Reports Record Second Quarter Results 4Henry Schein Reports Record Second Quarter Results 5Henry Schein Reports Record Second Quarter Results 6Henry Schein Reports Record Second Quarter Results 7Henry Schein Reports Record Second Quarter Results 8Henry Schein Reports Record Second Quarter Results 9Henry Schein Reports Record Second Quarter Results 10Henry Schein Reports Record Second Quarter Results 11Henry Schein Reports Record Second Quarter Results 12Henry Schein Reports Record Second Quarter Results 13Henry Schein Reports Record Second Quarter Results 14Henry Schein Reports Record Second Quarter Results 15Henry Schein Reports Record Second Quarter Results 16Henry Schein Reports Record Second Quarter Results 17Henry Schein Reports Record Second Quarter Results 18Henry Schein Reports Record Second Quarter Results 19Henry Schein Reports Record Second Quarter Results 20Henry Schein Reports Record Second Quarter Results 21Henry Schein Reports Record Second Quarter Results 22Henry Schein Reports Record Second Quarter Results 23Henry Schein Reports Record Second Quarter Results 24Henry Schein Reports Record Second Quarter Results 25
... Calif., Oct. 13 Luminous Medical, Inc. announced today ... of electrochemical sensors for exclusive rights to incorporate its ... Luminous is developing its monitor to enable clinicians to ... , Previously, Luminous was planning to use a sensing ...
... , NEWNAN, Ga., Oct. 13 CeloNova BioSciences, ... body, the British Standards Institution, to expand the ... may be used and to add a tenth ... http://www.newscom.com/cgi-bin/prnh/20081001/CLW080LOGO-b ) , (Photo: ...
Cached Medicine Technology:Luminous Medical, Inc. Secures Exclusive Rights to Glucose Sensor for Its Automated Glucose Monitor 2Minimally Invasive Device Approved to Treat Liver Cancer, Fibroids, Tumors, and Bleeding 2Minimally Invasive Device Approved to Treat Liver Cancer, Fibroids, Tumors, and Bleeding 3
(Date:7/29/2015)... ... 2015 , ... We are privileged to announce that U.S. News & World Report ... ophthalmology hospital in the nation for 2015-2016. This marks the 21st consecutive year that the ... “It is an honor to be included in the top 10 ophthalmology hospitals by U.S. ...
(Date:7/29/2015)... ... July 29, 2015 , ... Inspired ... Foundation in March, Steven W. Meier M.D., a prominent orthopedic surgeon and regenerative ... patients with demonstrated financial need. , “We are thrilled for this opportunity to ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... in a Clinical Performance Study for the Invisiport at Wheaton Franciscan Healthcare in ... catheter options, offers a less invasive, patient-friendly alternative to traditional chest ports and ...
(Date:7/29/2015)... St. Louis, MO (PRWEB) , ... July 29, ... ... in anticipation of a decision from the Judicial Panel on Multidistrict Litigation (JPML), ... updates and birth defects research at their website, the Zofran Birth Defects Lawsuit ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... The Woodlands ... encourage healthy lifestyles while donating to worthy charitable causes each month. The new system ... fitness boot camp. For each Check In at each facility, the boot camps will ...
Breaking Medicine News(10 mins):Health News:21 Years & Counting: The USC Eye Institute Ranks in the Top 10 Ophthalmology Hospitals in America 2Health News:21 Years & Counting: The USC Eye Institute Ranks in the Top 10 Ophthalmology Hospitals in America 3Health News:Orthopedic Surgeon Announces New Pro Bono Prolotherapy and Regenerative Medicine Clinic for Underserved Communities in Los Angeles 2Health News:Stealth Therapeutics Inc. Enrolls First Patients in a Clinical Performance Study for the Invisiport Product Line 2Health News:Stealth Therapeutics Inc. Enrolls First Patients in a Clinical Performance Study for the Invisiport Product Line 3Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 2Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 3Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 4Health News:Transforming Texan Lives and Bodies: Woodlands and Spring Fitness Boot Camps Commit to Multiple Charity Donations 2Health News:Transforming Texan Lives and Bodies: Woodlands and Spring Fitness Boot Camps Commit to Multiple Charity Donations 3
... Dec. 4 Aurora Health Care is ramping up ... Aurora,s Care Management,Clinical Leadership Team members committed this week ... D. The decision is in response to,growing evidence that ... heart disease, osteoporosis, certain muscle conditions and,seasonal depression. , ...
... WASHINGTON, Dec. 4 The U.S. Government, through the U.S. ... to help combat the cholera outbreak in Zimbabwe. This ... and hygiene emergency program USAID is already implementing in Zimbabwe. ... widespread, USAID was working alongside the international community to prepare ...
... seen with standard dose of daunorubicin, study shows , , ... of the chemotherapy drug daunorubicin prolonged survival for patients ... of a study sponsored by the U.S. National Cancer ... the blood and bone marrow. This study included 633 ...
... Reawakening a dormant gene could ease sickle-cell disease and thalassemia ... ... -- Researchers at Children,s Hospital Boston ( www.childrenshospital.org ) and ... blood cells to produce a form of hemoglobin normally made ...
... Toy Safety Program Offers Manufacturers A Way to Improve Toy ... Improvement Act , , ANN ... generate concerns among consumers about the safety of their children,s ... Safety team offers a solution -- integrated services that include ...
... Ill., Dec. 4 Omron Healthcare, Inc. reminds,consumers to ... Flex-,Spending Accounts (FSA,s) before they expire by purchasing products ... as home blood pressure,monitors and nebulizers. , ... , (Photo: ...
Cached Medicine News:Health News:Aurora Health Care Urges All Wisconsin Residents to Take Vitamin D 2Health News:USAID Increases Assistance for Zimbabwe Cholera Outbreak 2Health News:Higher Chemo Drug Dose Prolongs Lives of Leukemia Patients 2Health News:Turning back the Clock in Inherited Anemias 2Health News:Turning back the Clock in Inherited Anemias 3Health News:Turning back the Clock in Inherited Anemias 4Health News:NSF International Offers Answers to Rising Toy Safety Concerns 2Health News:Maximize Flex Spending Account Funds Before They Expire 2Health News:Maximize Flex Spending Account Funds Before They Expire 3
Microporous tape sheets for covering 96-well plates, square-well or flat-bottom blocks.;...
Microwell Plate Accessories...
ThermalSeal RT (2mil) is Optically Clear for Real Time PCR and easy to apply. Works for all plates....
Sealing tape featuring 3M adhesive technology. Superior optical properties. Low autofluorescense. Some residue will remain if using DMSO. Non-tacky to skin and gloves....
Medicine Products: